Vimta Labs Limited has informed the Exchange about Investor Presentation
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs filed a revised investor presentation (correcting typographical errors) detailing its Q1 FY26 results. Total income rose 31.4% YoY to Rs 993 Mn, EBITDA grew 33.1% to Rs 354 Mn with margins expanding to 35.7%, and PAT jumped 36% to Rs 189 Mn with a 19% margin. For full FY25, revenue stood at Rs 3,482 Mn, EBITDA at Rs 1,262 Mn (36.2% margin), and PAT at Rs 668 Mn. The company highlighted its leadership in pharma analytical and food testing, capacity expansion plans, and operational excellence as key growth drivers. It remains a net cash company with Rs 150 Mn cash vs Rs 70 Mn debt and a market cap of ~Rs 2,001 Cr.
This is a routine regulatory filing with no new material information beyond the already-disclosed Q1 results. The strong YoY growth and margin expansion reinforce the company's growth trajectory, which is positive for shareholders, but no fresh catalysts are introduced.